2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
	BRAVO
	1	0	0	0	0	0	0	1	0	0
	A REAL ADVANCE
	2	0	0	1	0	1	0	2	3	1(b)
	OFFERS AN ADVANTAGE
	14	6	3	3	3	3	6	5	5	5(c)
	POSSIBLY HELPFUL
	27	25	14	22	13	14	12	15	15	9
	NOTHING NEW
	79	57	62	49	53	42	48	35	43	56
	NOT ACCEPTABLE
	15	23	19	19	16	15	15	19	15	16(d)
	JUDGEMENT RESERVED
	3	9	6	3	7	7	9	10	6	5(e)
TOTAL	141	120	104	97	92	82	90	87	87	92
See: the year in review	2007 (pdf)	2008 (pdf)	2009 (pdf)	2010 (pdf)	2011 (pdf)	2012 (pdf)	2013 (pdf)	2014 (pdf)	2015 (pdf)	2016 (pdf)
For details on these categories, see: > Prescrire's drug ratings

a- About this table

This table includes new products (other than generics) and new indications, as well as products re-examined after longer follow-up.
For prior years (in French, subscription to French edition required):  > 1981-2000, > 1992-2006

b- The only drug rated "A REAL ADVANCE" in 2016 was:

• nivolumab in metastatic or inoperable BRAF V600 mutation-negative melanoma
  (Prescrire Int n° 177).

c- The drugs rated "OFFERS AN ADVANTAGE" in 2016 were:

• dexamethasone 40 mg in multiple myeloma (Rev Prescrire n° 395);
• entecavir in chronic hepatitis B in children (Prescrire Int n° 179);
• nivolumab in certain types of metastatic or inoperable lung cancer (Rev Prescrire n° 397);
• succimer 100 mg in lead or mercury poisoning (Rev Prescrire n° 392);
• trametinib in metastatic or inoperable BRAF V600 mutation-positive melanoma
  (Prescrire Int n° 177).

d- The drugs rated "NOT ACCEPTABLE" in 2016 were:

• adalimumab in hidradenitis suppurativa (Prescrire Int n° 181);
• capsaicin in painful diabetic neuropathy (Prescrire Int n° 180);
• ceritinib in certain types of non-small cell lung cancer (Prescrire Int n° 174);
• ciclosporin eye drops in dry eye disease (Prescrire Int n° 181);
• the estradiol + dydrogesterone 0.5 mg/2.5 mg combination in postmenopausal hormone replacement therapy (Rev Prescrire n° 388);
• febuxostat in hyperuricaemia associated with tumour lysis syndrome (Prescrire Int n° 173);
• idebenone in Leber’s hereditary optic neuropathy (Prescrire Int n° 179);
• the insulin degludec + liraglutide combination in type 2 diabetes (see page 121);
• mepolizumab in severe refractory asthma (Prescrire Int n° 179);
• nintedanib in certain types of inoperable non-small cell lung cancer (Rev Prescrire n° 389);
• nintedanib in idiopathic pulmonary fibrosis (Prescrire Int n° 173);
• olaparib in certain types of ovarian cancer (Prescrire Int n° 178);
• panobinostat in multiple myeloma (Prescrire Int n° 176);
• prucalopride in chronic constipation in men (Prescrire Int n° 175);
• the simvastatin + fenofibrate combination in hypercholesterolaemia and hypertriglyceridaemia (Prescrire Int n° 173);
• tigecycline in serious infections in children (Prescrire Int n° 173).

e- The drugs rated "JUDGEMENT RESERVED" in 2016 were:

• denosumab in giant cell tumour of bone (Rev Prescrire n° 388);
• empagliflozin, alone or combined with metformin in type 2 diabetes (Prescrire Int n° 172);
• ibrutinib in chronic lymphocytic leukaemia and mantle cell lymphoma (Prescrire Int n° 170);
• lenvatinib in differentiated thyroid carcinoma (Rev Prescrire n° 398);
• the RTS,S/AS01E malaria vaccine for immunisation of children against malaria and hepatitis B (Prescrire Int n° 178).

 

©Prescrire 1 May 2017

"New products and new indications in 2016: a system that favours imitation over the pursuit of real progress" Prescrire Int 2017; 26 (182): 136-139. (Pdf, free)